Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.362 EUR | +3.18% | +6.24% | -56.62% |
05-24 | Renovaro, Amsterdam UMC Cancer Center Plan to Form Joint Venture for Cancer Immunotherapy | MT |
05-24 | Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy | CI |
Business Summary
Number of employees: 12
Managers
Managers | Title | Age | Since |
---|---|---|---|
Mark Dybul
CEO | Chief Executive Officer | 60 | 22/01/18 |
Lester Russell
CTO | Chief Tech/Sci/R&D Officer | - | 20/08/23 |
Greg Duczynski
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/15 |
Joseph R. Cohen
CTO | Chief Tech/Sci/R&D Officer | - | - |
François Binette
COO | Chief Operating Officer | - | 19/04/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Gregg Alton
BRD | Director/Board Member | 58 | 31/12/19 |
Avram Miller
BRD | Director/Board Member | - | 10/10/23 |
James Sapirstein
BRD | Director/Board Member | 63 | 05/03/18 |
Director/Board Member | 60 | 03/10/23 | |
Director/Board Member | 78 | 03/10/23 | |
Carol Brosgart
BRD | Director/Board Member | 72 | 26/12/19 |
Rene Sindlev
CHM | Chairman | 61 | 17/01/11 |
Mark Dybul
CEO | Chief Executive Officer | 60 | 22/01/18 |
Jayne McNicol
BRD | Director/Board Member | 57 | 24/05/21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 147,504,944 | 109,814,931 ( 74.45 %) | 0 | 74.45 % |
Stock B | 0 | 561,010 | 0 | 0 |
Company contact information
Renovaro, Inc.
1927 Paseo Rancho Castillo
90032-2012, Los Angeles
+45 39 17 98 40
http://www.enochianbio.comSector
1st Jan change | Capi. | |
---|---|---|
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- RENB Stock
- 2Q5 Stock
- Company Renovaro Inc.